ArticlebioRxiv : the preprint server for biology2022
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
Linglei Jiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.